Harvey Farrington
Interim Chief Financial Officer / Artrya
| Rank | Company | # | |
|---|---|---|---|
| 90th | - | Volt Group | $5.90m |
| 91st | - | Botanix Pharmaceuticals | $5.79m |
| 92nd | - | Holista CollTech | $5.66m |
| 93rd | - | Artrya | $5.49m |
| Rank | Company | 1 Yr | 5 Yr |
|---|---|---|---|
| 22nd | Kula Gold | 658.85% | 4.68% |
| 23rd | Holista CollTech | 650% | 7.15% |
| 24th | Artrya | 645.42% | 0% |
| 25th | Almonty Industries | 610.86% | 0% |
| 26th | Nyrada Inc | 609.97% | 27% |
|
NEWS: Tagged in Board moves July 2, 2025 | 02 Jul 2025 |
|
NEWS: Tagged in Artrya announces executive changes | 02 Jul 2025 |
|
NEW ROLE: Interim Chief Financial Officer, Artrya | 02 Jul 2025 |
Access to our data for Harvey Farrington is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Harvey Farrington is linked to 1 organisation which is included in 2 lists - Public Companies - Industrial WA and Technology Companies.
To see the data you will need to Subscribe.